---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042647"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:04:52.054339+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences Q4 revenue +56% YoY to $1.2M; net loss widens; Roosevelt deal on track

## Summary
- Q4 total revenues $1.216M (+56% YoY); FY2024 revenues $5.045M (+13% YoY).
- Net loss attributable to common stockholders Q4 $4.064M ($2.98/share) vs $2.853M in Q4 2023.
- Full-year net loss improved to $7.038M ($3.17/share) from $13.981M in 2023.
- Zola coconut water revenue up 124% in Q4 and 46% for full year.
- Pending merger with Roosevelt Resources; post-close owners get ~90% of shares, Arcadia holders ~10%.

## SEC filing metadata
- accession: 0000950170-25-042647
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/0000950170-25-042647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/rkda-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042647
- JSON: https://secwatch.observer/filing/0000950170-25-042647.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.